Wire · opportunities
Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Ono Pharmaceutical has secured exclusive rights from Biohaven to develop and commercialize Biohaven's IgG degrader portfolio, including BHV-1300 in Japan, South Korea, Taiwan, and ASEAN countries, targeting autoimmune diseases such as Graves' disease. This collaboration combines Biohaven’s innovative drug platform with Ono’s development and commercialization capabilities in key Asian markets.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a direct route to bring a novel therapy targeting autoimmune diseases to major Asian markets with clinical and commercial backing. Act on partnerships and regulatory pathways this quarter to capitalise on Graves' disease treatment gaps.
◆ Coverage
1 source · 8 Oct 2026
◆ Related on Wire
◆ Topics